CD274 and adrenal carcinoma: Future work will expand this approach to additional indications, such as squamous cell carcinoma of the head and neck (SSCHN) and gastric and gastric of adrenal carcinomas, where CPS-based decisions of patient treatment make the assessment of immune cells and their PD-L1 positivity status even more crucial to the accuracy of those assays.